Covidien International Finance S.A. develops, manufactures, and sells healthcare products for use in clinical and home settings. The company operates in three segments: Medical Devices, Pharmaceutical Products, and Medical Supplies. The Medical Devices segment develops, manufactures, and sells endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Pharmaceutical Products segment is involved in the development, manufacture, and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products, and radiopharmaceuticals. The Medica...
3b Boulevard Prince Henri
Covidien International Finance S.A. Enters into Amended and Restated Five-Year Senior Credit Agreement
May 28 14
On May 23, 2014, covidien plc entered into an amended and restated five-year senior credit agreement by and among the company, as guarantor, Covidien International Finance S.A., a subsidiary of the company, as borrower, Citibank, N.A., as administrative agent and various lenders, providing for a senior unsecured revolving credit facility in the aggregate amount of $1.5 billion. Covidien International Finance S.A. may, at its option, seek to increase the aggregate commitment under the amended and restated credit agreement by up to $500 million up to a maximum aggregate commitment of $2.0 billion provided that the relevant borrowing conditions under the credit agreement are met at that time. The proceeds of loans under the amended and restated credit agreement can be used for working capital, capital expenditures and other lawful corporate purposes. The amended and restated credit agreement amends and restates the terms of the five-year credit agreement dated as of august 9, 2011 which was scheduled to mature in august 2016, under which Covidien International Finance S.A. was also the borrower and the company was also a guarantor. Capitalized terms used herein and not otherwise defined have the meanings set in the amended and restated credit agreement. Borrowings under the amended and restated credit agreement will bear interest at a rate per annum equal to, at Covidien International Finance S.A.’s option, any of the following, plus, in each case, an applicable margin: (a) a base rate determined by reference to the higher of (1) the base rate of Citibank, N.A., (2) the federal funds effective rate plus 0.50% and (3) LIBOR for an interest period of one month plus 1.00% or (b) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the relevant interest period adjusted for certain additional costs. the applicable margin for borrowings under the amended and restated credit agreement is subject to adjustments based on the credit ratings for the senior, unsecured, long-term indebtedness of Covidien International Finance S.A. that is not guaranteed by any other person other than the company or Covidien Ltd. or subject to any other credit enhancement and varies from 0 basis points to 50 basis points with respect to base rate borrowings and from 75 basis points to 150 basis points with respect to libor borrowings. in addition, Covidien International Finance S.A. is required to pay a commitment fee between 6 and 22.5 basis points (depending on the credit ratings of Covidien International Finance S.A.’s senior, unsecured, long-term indebtedness that is not guaranteed by any other person other than the company or Covidien Ltd. or subject to any other credit enhancement) on the aggregate unused commitments under the amended and restated credit agreement. The amended and restated credit agreement contains financial and other covenants, including a financial covenant requiring the maintenance of a 3.5 to 1.0 maximum ratio of the company’s consolidated total debt to its consolidated EBITDA, each as defined in the amended and restated credit agreement, as well as events of default with respect to the company, Covidien International Finance S.A. and in some circumstances their significant subsidiaries, which covenants and events of default are customary for facilities of this type. The negative covenants of the amended and restated credit agreement are substantially similar to those in the 2011 credit agreement referred to above, and include, among other things, limitations (each of which is subject to customary exceptions for facilities of this type) on the ability of the company and any subsidiary, including Covidien International Finance S.A., to grant liens; enter into transactions resulting in fundamental changes (such as mergers or sales of all or substantially all of the assets of the company or Covidien International Finance S.A.); restrict dividends or other distributions by any subsidiary, other than cifsa; and enter into transactions with affiliates. The obligations of the lenders under the amended and restated credit agreement to provide advances will terminate on the earlier of (i) May 23, 2019 and (ii) the date on which the commitments shall have been reduced to zero or terminated in whole pursuant to the terms of the credit agreement, including by reason of an event of default. The amended and restated credit agreement provides that Covidien International Finance S.A. will have the right to extend the termination date for the credit facility for up to two additional one-year periods, subject to obtaining commitments from existing lenders or, in certain circumstances, third-party financial institutions for such extension, and subject to the satisfaction of certain other customary conditions.
Covidien International Finance S.A. Prices Underwritten Offering of $750 Million Aggregate Principal Amount of 2.950% Senior Notes Due 2023
May 17 13
Covidien plc announced that its subsidiary, Covidien International Finance S.A. (CIFSA), priced an underwritten offering of $750 million aggregate principal amount of 2.950% senior notes due 2023. The company noted that the offering is expected to close on May 16, 2013. CIFSA intends to use the net proceeds of this offering to fund the repayment at maturity of all of its outstanding 1.875% senior notes due June 2013 and for general corporate purposes.